Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer
CPT: Pharmacometrics & Systems Pharmacology · 2025-04 · 14 (4) · 726-737
DOI: 10.1002/psp4.13310 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 05.02.2025. Verfasst von Phyllis Chan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, South San Francisco, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Humanized, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
IMscin001 is a two‐part dose‐finding (Phase Ib) and ‐confirmation (Phase III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC). The objectives of the current analyses were to characterize the population pharmacokinetics (popPK) of atezolizumab and to determine the relationship between atezolizumab exposure and safety and efficacy endpoints in IMscin001. A previously validated IV popPK model was extended to add SC absorption parameters using SC and IV data from Phase Ib and Phase III of IMscin001 ( N = 435), and covariate effects were investigated on the SC absorption parameters. The exposure‐response (ER) investigation was performed using SC data following 1875 mg every three weeks (q3w) administration in the Phase III portion of IMscin001 ( N = 246). The clinical endpoints were objective response rate, progression‐free survival, or overall survival for efficacy, serious adverse events, special interest adverse events, Grades 3–5 adverse events, infusion‐related reaction, or injection site reactions for safety. Atezolizumab SC absorption was characterized by a first‐order absorption with a bioavailability of 71.8% and an absorption rate constant of 0.304 day −1 . The extended popPK model was adequate to predict atezolizumab PK after IV and SC administrations and to predict individual exposure metrics. For all efficacy and safety endpoints, atezolizumab exposure was not statistically significant ( p ‐value > 0.05) in the ER models. The non‐inferior popPK exposure and flat ER results supported atezolizumab SC dose at 1875 mg q3w.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genentech, South San Francisco, USA.
- Certara Inc., Montreal, Canada.
- Certara Inc., Marseille, France.
- Roche, Basel, Switzerland.
- Genentech/Roche, Lyon, France.
ORCID-Profile: Phyllis Chan, Mathilde Marchand, Pascal Chanu
Zitieren
APA
Chan, P., Liu, S. N., Gosselin, N., Sauve, Z., Marchand, M., Lin, A., Herraez-Baranda, L., Zanghi, J., Shearer-Kang, E., Liu, X., Wu, B., & Chanu, P. (2025). Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer. CPT: Pharmacometrics & Systems Pharmacology, 14(4), 726-737. https://doi.org/10.1002/psp4.13310
Vancouver
Chan P, Liu SN, Gosselin N, Sauve Z, Marchand M, Lin A, et al. Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(4):726-737. doi:10.1002/psp4.13310
BibTeX
@article{Chan2025,
author = {Chan, Phyllis and Liu, Stephanie N and Gosselin, Nathalie and Sauve, Zacharie and Marchand, Mathilde and Lin, Alyse and Herraez-Baranda, Luis and Zanghi, James and Shearer-Kang, Esther and Liu, Xiaoyan and Wu, Benjamin and Chanu, Pascal},
title = {Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
volume = {14},
number = {4},
pages = {726--737},
doi = {10.1002/psp4.13310}
}
EUVIMED